AU
Arthritis UK (formerly Versus Arthritis)

Osteoarthritis Treatments Research Consortium

Funds a UK osteoarthritis drug-development consortium, up to £3 million over 5 years.

The Osteoarthritis Treatments Research Consortium is a grant from Arthritis UK (formerly Versus Arthritis) funding a single UK consortium to develop disease- and symptom-modifying osteoarthritis treatments, from small molecules and biologics to gene and cell therapies, regenerative medicine and repurposed existing drugs. This is a single-stage application process, but it opens with a mandatory Not

This second osteoarthritis consortium call backs disease- and symptom-modifying pharmacotherapeutic treatments, spanning small molecules, biologics, gene and cell therapies, and regenerative medicine, plus repurposing existing drugs with known safety profiles. It wants a distributed portfolio of multiple treatments at different development stages, building a strong UK translational research community able to move quickly.

CycleiHow often this grant runs - e.g. annually, on a rolling basis, or a one-off call.No fixed schedule
Next deadlineiThe next date applications are due. Rolling means you can apply any time.23 Sept 2026
Decision timeiTypical time from the deadline to the funder's decision.-
Project durationiHow long the funded work is expected to run.1–60 months
Award typeiThe form of funding - grant, equity, loan, tax credit, etc.Grant
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.-
Funding pooliThe total budget available across all awards in this round.-

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see what you submit

Sign up free to see the timeline

Sign up free to see where teams trip up

Guides for this application

All guides →